PDF下载 ( 1446 KB)
Long-term relief in patients with hepatocellular carcinoma treated with donafenib tosylate: a report of two cases
-
摘要: <正>原发性肝癌在肿瘤相关性死亡中排第3位[1],由于起病隐匿、进展迅速,临床上仅有不足30%的患者就诊时可获得手术治疗的机会,因此,非手术疗法是中晚期肝癌的主要治疗方式[2]。目前以索拉非尼为代表的激酶抑制剂成为第一个治疗原发性肝癌的靶向治疗药物[3-5]。甲苯磺酸多纳非尼将索拉非尼分子上的一个甲基取代为三氘代甲基后形成全新结构的新药,与索拉非尼具有相似的分子结构和作用机制。笔者在多纳非尼的ⅠB期临床试验中,发现2例
-
Key words:
- liver neoplasms /
- targeted therapy /
- case reports
-
[1]FERLAY J, SHIN HR, BRAY F, et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer, 2010, 127:2893-2917. [2]LI Y, CHENG P.Advances in treatment of advanced hepatocellular cancer[J].J Clin Hepatol, 2014, 30 (3) :1001-5256. (in Chinese) 李焱, 程鹏, 中晚期肝癌临床治疗进展[J].临床肝胆病杂志, 2014, 30 (3) :1001-5256. [3]ZHANG WJ, LU SY.Advances in molecularly targeted therapy of hepatocellular carcinoma[J].World Chin J Dig, 2011, 19 (4) :331-337. (in Chinese) 张文杰, 禄韶英.肝细胞癌的分子靶向治疗[J].世界华人消化杂志, 2011, 19 (4) :331-337. [4]WU MC.Current development on surgical treatment of liver cancer[J].Chin J Bases Clin Gen Surg, 2006, 13 (2) :125-128. (in Chinese) 吴孟超.肝癌外科治疗的近期进展[J].中国普外基础与临床杂志, 2006, 13 (2) :125-128. [5]QIN SK, GONG XL.Progress on treatment of sorafenib on hepatocellular carcinoma[J].Chin Clin Oncol, 2008, 13 (12) :1057-1068. (in Chinese) 秦淑逵, 龚新雷.索拉非尼治疗原发性肝癌的研究进展[J].临床肿瘤学杂志, 2008, 13 (12) :1057-1068. [6]STEFANIUK P, CIANCIARA J, WIERCINSKA-DRAPALO A.Present and future possibilities for early diagnosis of hepatocellular carcinoma[J].World J Gastroenterol, 2010, 16 (4) :418-424. [7]ZHANG N, GU J, YIN L, et al.Incorporation of alpha-fetoprotein (AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database[J].Oncotarget, 2016, 7 (49) :81389-81401. -
本文二维码
计量
- 文章访问数: 2964
- HTML全文浏览量: 14
- PDF下载量: 475
- 被引次数: 0
下载:
